



Is The Largest Nonprofit Funder Of Alzheimer's And All Other  
Dementia Research In The World

More Than   
**\$450**  
Million Dollar

In Over  **1200**  
Active best-in-field  
research projects in

**56** countries

This Includes Over  
 **\$78** Million Dollar In New  
Scientific Investigations

And Over  
 **\$112** Million Dollar In  
Total Research  
Investment

## INTERNATIONAL RESEARCH GRANT PROGRAM (IRGP)

### 2025 AT A GLANCE



Newly funded projects are advancing research on Alzheimer's and other diseases that cause cognitive decline and dementia across five essential areas:





# STRATEGIC RESEARCH INITIATIVES

In 2025, the Alzheimer's Association awarded **35 Strategic Research Initiatives** worldwide to accelerate prevention, diagnosis, & treatment of Alzheimer's & other dementias.

## LIFESTYLE & MULTIDOMAIN INTERVENTION TRIALS

Providing the essential funding for the two year lifestyle intervention trial – known as U.S. POINTER – testing whether a specific intervention simultaneously targeting multiple risk factors in an at risk population is able to benefit cognition, and the important funding to continue to track the long term outcomes through the U.S. POINTER Alumni Extension.

Building off the momentum of multidomain lifestyle interventions, such as U.S. POINTER, the Association's Alzheimer's Association WorldWide FINGERS Network Fund Program (ALZ WW-FNFP) advances multidomain lifestyle intervention trials for dementia prevention studies around the world, including funding of thirteen grants to the LatAm FINGERS Extension Study continues follow-up in 11 Latin American countries to assess long-term effects on brain health.

## The next frontier of research studies will require the collection & utilization of real world data.

- The Alzheimer's Association is actively investing and leading ALZ-NET, the Alzheimer's Network for Treatment and Diagnostics, while also supporting an Innovative funding mechanism through the Alzheimer's Association Funding Program for Global Real-World Data Platforms (ALZ-RWD). To support global real-world data infrastructure for Alzheimer's research, including two projects to Dr. Casper de Boer (ABOARD Cohort, Amsterdam UMC) and Dr. Christopher Rowe (ADNeT, University of Melbourne).
- Dedicated funding for the Veterans Administration (VA) to build the real world data linkage between the VA network and ALZ-NET.

## Continuing the long-standing commitment to the DIAN-TU (Dominantly Inherited Alzheimer's Network Trials Unit) with over \$50 million invested in the following initiatives:

- DIAN-TU ART: Long-term treatment with monoclonal anti-amyloid antibodies to understand the long term impact of amyloid removal.
- DIAN-TU primary prevention study to intervene with an amyloid-targeting treatment in individuals with a dominant mutation to determine if it can prevent disease progression
- DIAN-TU Tau NexGen to advance the field's first combination trial targeting both tau and amyloid together.
- Building the network of families engaged through the network by providing support for the DIAN LATAM, engaging Latin America, and bridge funding to support international sites of the full network due to changes in their NIH funding.

## Targeted investment in key projects to advance key efforts in AD/ABDRD research

- A new collaboration with the American Association of Family Practitioners (AAFP) and University of Washington Cognitive Care Project to test an innovative model that will support primary care clinicians with tools to identify and manage cognitive impairment using evidence-based strategies.
- Providing bridge funding for the LiBBY Open Label Extension (University of Southern California) to test a THC/CBD therapy for agitation in late-stage dementia and its impact on caregiving burden.
- Funding to Dr. Henrik Zetterberg (University of Gothenburg) and Dr. Nicholas Ashton (Banner Health) supports the Alzheimer's Association Certified Reference Material and Method for Plasma p-Tau217 that expands work from the The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) to advance reliable blood biomarkers for Alzheimer's.